Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors

Expert Opinion on Drug Discovery

Volumn 6, Issue 8, 2011, Pages 811-825

  Stallaert, Wayne ^a   Christopoulos, Arthur ^b   Bouvier, Michel ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Efficacy; GPCRs; Potency; Selectivity; Signaling

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; BUCINDOLOL; CARVEDILOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENTANYL; FOCAL ADHESION KINASE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; G PROTEIN COUPLED RECEPTOR; LABETALOL; LIGAND; METOPROLOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MORPHINE; PROPRANOLOL; PROTEIN C JUN; PROTEIN KINASE C; SEROTONIN 2C RECEPTOR;

BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEART FAILURE; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 79960502280     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.586691     Document Type: Review

References (118)

1. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011;10:47-60
2. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002;3:639-50 (Pubitemid 34987785)
3. Stephenson RP. A modification of receptor theory. Br J Pharmacol Chemother 1956;11:379-93
4. Chidiac P, Hebert TE, Valiquette M, et al. Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 1994;45:490-9 (Pubitemid 24094939)
5. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 2004;65:2-11 (Pubitemid 38113879)
6. Bond R, Leff P, Johnson T, et al. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta2-adrenoceptor. Nature 1995;374:272-6
7. Costa T, Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 1989;86:7321-5 (Pubitemid 19254452)
8. Samama P, Cotecchia S, Costa T, et al. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 1993;268:4625-36 (Pubitemid 23081571)
9. Samama P, Pei G, Costa T, et al. Negative Antagonists promote an inactive conformation of the beta2-Adrenergic receptor. Mol Pharmacol 1994;45:390-4
10. Lefkowitz RJ, Cotecchia S, Samama P, et al. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 1993;14:303-7 (Pubitemid 23242583)
11. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther 2003;99:25-44 (Pubitemid 36694748)
12. Bockaert J, Fagni L, Dumuis A, et al. GPCR interacting proteins (GIP). Pharmacol Ther 2004;103:203-21 (Pubitemid 39298464)
13. Brady A, Limbard L. G protein-coupled receptor interacting proteins: Emerging roles in localization and signal transduction. Cell Signal 2002;14:297-309 (Pubitemid 34164685)
14. Urban JD, Clarke W, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007;320(1):13
15. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 1995;16:232-8
16. Spengler D, Waeber C, Pantaloni C, et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993;365:170-5 (Pubitemid 23282064)
17. Robb S, Cheek TR, Hannan FL, et al. Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems. EMBO J 1994;13:1325
18. Mottola DM, Kilts JD, Lewis MM, et al. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 2002;301:1166-78 (Pubitemid 34595111)
19. Kilts JD, Connery HS, Arrington EG, et al. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 2002;301:1179-89 (Pubitemid 34595112)
20. Sato M, Horinouchi T, Hutchinson DS, et al. Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4- tetrahydronapth-1-ylamino]-2S-2- propanol oxalate (SR59230A) relative to receptor agonists. Mol Pharmacol 2007;72:1359-68 (Pubitemid 350012609)
21. De Deurwaerdere P, Navailles S, Berg KA, et al. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 2004;24:3235-41 (Pubitemid 38451889)
22. Berg K, Maayani S, Goldfarb J, et al. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 1998;54:94-104 (Pubitemid 28337591)
23. Reiner S, Ambrosio M, Hoffmann C, et al. Differential signaling of the endogenous agonists at the {beta}2-adrenergic receptor. J Biol Chem 2010;285:36188-98
24. Kohout T, Nicholas SL, Perry SJ, et al. Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem 2004;279:23214-22 (Pubitemid 38685628)
25. Nickolls SA, Fleck B, Hoare SRJ, et al. Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists : evidence for ligand-specific conformational states. J Pharmacol Exp Ther 2005;313:1281-8 (Pubitemid 40727033)
26. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010;9:373-86
27. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 2010;62:305-30
28. Violin JD, Dewire SM, Yamashita D, et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac. J Pharmacol Exp Ther 2010;335:572-9
29. Azzi M, Charest PG, Angers S, et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 2003;100:11406-11 (Pubitemid 37205948)
30. Werry TD, Gregory KJ, Sexton PM, et al. Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J Neurochem 2005;93:1603-15 (Pubitemid 40853284)
31. Audet N, Paquin-Gobeil M, Landry-Paquet O, et al. Internalization and Src activity regulate the time course of ERK activation by delta opioid receptor ligands. J Biol Chem 2005;280:7808-16 (Pubitemid 40349675)
32. Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 2006;70:1575-84
33. Wisler JW, Dewire SM, Whalen EJ, et al. A unique mechanism of beta-blocker action Carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 2007;104:16657-62 (Pubitemid 350211072)
34. Metra M, Cas LD, di Lenarda A, et al. Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev 2004;9:123-30 (Pubitemid 39485473)
35. Gainetdinov RR, Premont RT, Bohn LM, et al. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004;27:107-44 (Pubitemid 39050399)
36. Wolfe BL, Trejo J. Clathrin-dependent mechanisms of G protein-coupled receptor endocytosis. Traffic 2007;8:462-70 (Pubitemid 46638559)
37. Kelly E, Bailey CP, Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 2008;153:(Suppl):S379-88 (Pubitemid 351340999)
38. Trester-Zedlitz M, Burlingame A, Kobilka B, et al. Mass spectrometric analysis of agonist effects on posttranslational modifications of the beta-2 adrenoceptor in mammalian cells. Biochemistry 2005;44:6133-43 (Pubitemid 40570706)
39. Luk T, Jin W, Zvonok A, et al. Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol 2004;142:495-500 (Pubitemid 38869863)
40. Stout BD, Clarke WP, Berg K. Rapid desensitization of the serotonin(2C) receptor system: effector pathway and agonist dependence. J Pharmacol Exp Ther 2002;302:957-62 (Pubitemid 34920216)
41. Roettger B, Ghanekar D, Rao R, et al. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 1997;51:357
42. Pheng LH, Dumont Y, Fournier A, et al. Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells. Br J Pharmacol 2003;139:695-704 (Pubitemid 36819596)
43. Sneddon WB, Syme CA, Bisello A, et al. Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J Biol Chem 2003;278:43787-96 (Pubitemid 37346007)
44. Bhowmick N, Narayan P, Puett D. The endothelin subtype A receptor undergoes agonist- and antagonist-mediated internalization in the absence of signaling. Endocrinology 1998;139:3185-92 (Pubitemid 28512348)
45. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 2001;56:441-51 (Pubitemid 34031779)
46. Pradhan AAA, Walwyn W, Nozaki C, et al. Ligand-directed trafficking of the delta-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosc 2010;30:16459-68
47. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 2005;4:919-27 (Pubitemid 41637694)
48. Thomas WG, Qian H, Chang CS, et al. Agonist-induced phosphorylation of the angiotensin II (AT(1A)) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. J Biol Chem 2000;275:2893-900 (Pubitemid 30082064)
49. Zidar D, Violin JD, Whalen EJ, et al. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci USA 2009;106:9649-54
50. Johnson EA, Oldfield S, Braksator E, et al. Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol 2006;70:676
51. Whistler JL, Zastrow M. von Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 1998;95:9914-19 (Pubitemid 28415269)
52. Chu J, Zheng H, Loh HH, et al. Morphine-induced mu-opioid receptor rapid desensitization is independent of receptor phosphorylation and beta-arrestins. Cell Signal 2008;20:1616-24
53. Zeitz KP, Malmberg AB, Gilbert H, et al. Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice. Pain 2001;94:245-53 (Pubitemid 33145394)
54. Smith FL, Gabra BH, Smith PA, et al. Determination of the role of conventional, novel and atypical PKC isoforms in the expression of morphine tolerance in mice. Pain 2007;127:129-39 (Pubitemid 44959434)
55. Terman GW, Jin W, Cheong Y-P, et al. G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol 2004;141:55-64 (Pubitemid 38241163)
56. Ferguson SS, Zhang J, Barak LS, et al. Molecular mechanisms of G protein-coupled receptor desensitization and resensitization. Life Sci 1998;62:1561-5 (Pubitemid 28210241)
57. Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 2001;32:829-39 (Pubitemid 34024844)
58. Berger AC, Whistler JL. How to design an opioid drug that causes reduced tolerance and dependence. Ann Neurol 2010;67:559-69
59. Vaidehi N, Kenakin T. The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol 2010;10:775-81
60. Kobilka BK, Deupi X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 2007;28:397-406 (Pubitemid 47087966)
61. Gether U, Lin S, Kobilka BK. Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem 1995;270:28268-75
62. Swaminath G, Xiang Y, Lee TW, et al. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem 2004;279:686-91 (Pubitemid 38044873)
63. Ghanouni P, Gryczynski Z, Steenhuis JJ, et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 2001;276:24433-6
64. Yao X, Parnot C, Deupi X, et al. Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol 2006;2:417-22 (Pubitemid 44114919)
65. Vilardaga J-P, Steinmeyer R, Harms GS, et al. Molecular basis of inverse agonism in a G protein-coupled receptor. Nat Chem Biol 2005;1:25-8
66. Bisello A, Chorev M, Rosenblatt M, et al. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J Biol Chem 2002;277:38524-30 (Pubitemid 35154711)
67. Li JH, Han S-J, Hamdan FF, et al. Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands. J Biol Chem 2007;282:26284-93 (Pubitemid 47443813)
68. Li JH, Hamdam FF, Kim S-K, et al. Ligand-specific changes in M3 muscarinic acetylcholine receptor structure detected by a disulfide scanning strategy. Biochemistry 2008;47:2776-88 (Pubitemid 351328828)
69. Audet N, Gales C, Archer-Lahlou E, et al. Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. J Biol Chem 2008;283:15078-88
70. Alves ID, Salamon Z, Varga E, et al. Direct observation of G-protein binding to the human delta-opioid receptor using plasmon-waveguide resonance spectroscopy. J Biol Chem 2003;278:48890-7
71. Yao XJ, Velez Ruiz G, Whorton MR, et al. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci USA 2009;106:9501-6
72. Gales C, Van Durm JJJ, Schakk et al. Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol 2006;13:778-86 (Pubitemid 44338771)
73. Nikolaev VO, Hoffmann C, Bunemann M, et al. Molecular basis of partial agonism at the neurotransmitter alpha2A-adrenergic receptor and Gi-protein heterotrimer. J Biol Chem 2006;281:24506-11 (Pubitemid 44274225)
74. Wei H, Ahn S, Shenoy SK, et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 2003;100:10782-7 (Pubitemid 37140105)
75. Galandrin S, Oligny-Longpre G, Bonin H, et al. Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol Pharmacol 2008;74:162-72 (Pubitemid 351872167)
76. Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature 2009;459:356-63
77. Cherezov V, Rosenbaum DM, Hanson M, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007;318:1258-65 (Pubitemid 350172884)
78. Chien EYT, Liu W, Zhao Q, et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010;330:1091-5
79. Rasmussen SGF, Choi H-J, Rosembaum DM. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007;450:383-7 (Pubitemid 350126755)
80. Warne T, Serrano-Vega MJ, Baker JG, et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008;454:486-91
81. Jaakola VP, Griffith MT, Hanson MA, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008;322:1211
82. Wu B, Chien EYT, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010;330:1066-71
83. Rasmussen SGF, Choi H-J, Fung JJ, et al. Structure of a nanobody-stabilized active state of the beta2 adrenoceptor. Nature 2011;469:175-80
84. Rosenbaum DM, Zhang C, Lyons J, et al. Structure and function of an irreversible agonist-beta2 adrenoceptor complex. Nature 2011;469:236-40
85. Warne T, Moukhametzianov R, Baker JG, et al. The structural basis for agonist and partial agonist action on a beta1-adrenergic receptor. Nature 2011;469:241-4
86. Goncalves J, South K, Ahuja S, et al. Highly conserved tyrosine stabilizes the active state of rhodopsin. Proc Natl Acad Sci USA 2010;107:19861-6
87. Bokoch MP, Zou Y, Rasmussen SGF, et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010;463:108-12
88. Stewart GD, Sexton PM, Christopoulos A. Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae. Mol Pharmacol 2010;78:205-14
89. Stewart GD, Sexton PM, Christopoulos A. Detection of novel functional selectivity at M3 muscarinic acetylcholine receptors using a Saccharomyces cerevisiae platform. ACS Chem Biol 2010;5:365-75
90. Stewart GD, Valant C, Dowell SJ, et al. Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity. J Pharmacol Exp Ther 2009;331:277-86
91. Jiang LI, Collins J, Davis R, et al. Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J Biol Chem 2007;282:10576-84 (Pubitemid 47093456)
92. Charest PG, Terrillon S, Bouvier M. Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep 2005;6:334-40 (Pubitemid 40561625)
93. Breton B, Lagace M, Bouvier M. Combining resonance energy transfer methods reveals a complex between the {alpha}2A-adrenergic receptor, G{alpha}i1 {beta}1{gamma}2, and GRK2. FASEB J 2010;24:1-11
94. Gorokhovatsky AY, Marchenkov VV, Rudenko NV, et al. Fusion of Aequorea victoria GFP and aequorin provides their Ca(2+)-induced interaction that results in red shift of GFP absorption and efficient bioluminescence energy transfer. Biochem Biophys Res Commun 2004;320:703-11 (Pubitemid 38887200)
95. Huwiler KG, Machleidt T, Chase L, et al. Characterization of serotonin 5-hydroxytryptamine-1A receptor activation using a phospho-extracellular-signal regulated kinase 2 sensor. Anal Biochem 2009;393:95-104
96. Fosbrink M, Aye-Han N-N, Cheong R, et al. Visualization of JNK activity dynamics with a genetically encoded fluorescent biosensor. Proc Natl Acad Sci USA 2010;107:5459-64
97. Hodgson L, Shen F, Hahn K. Biosensors for characterizing the dynamics of rho family GTPases in living cells. Curr Protocols Cell Biol 2010;46:14.11.1-26
98. Depry C, Allen M, Zhang J. Visualization of PKA activity in plasma membrane microdomains. Molecular BioSystems 2011;7:52-8
99. Nishioka T, Frohman MA, Matsuda M, et al. Heterogeneity of phosphatidic acid levels and distribution at the plasma membrane in living cells as visualized by a forster resonance energy transfer (FRET) biosensor. J Biol Chem 2010;285:35979-87
100. Depry C, Allen MD, Zhang J. Visualization of PKA activity in plasma membrane microdomains. Mol Biosyst 2010;7:52-8
101. Lin C, Kolossov VL, Tsvid G, et al. Imaging in real-time with FRET the redox response of tumorigenic cells to glutathione perturbations in a microscale flow. Integrative biology (Cambridge) 2011;3:208-17
102. Harvey CD, Ehrhardt AG, Cellurale C, et al. A genetically encoded fluorescent sensor of ERK activity. Proc Natl Acad Sci USA 2008;105:19264-9
103. Breton B, Sauvageau E, Zhou J, et al. Multiplexing of multicolor bioluminescence resonance energy transfer. Biophys J 2010;99:4037-46
104. Scott CW, Peters MF. Label-free whole-cell assays: expanding the scope of GPCR screening. Drug Discov Today 2010;15:704-16
105. Yu N, Atienza JM, Bernard J, et al. Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors. Anal Chem 2006;78:35-43 (Pubitemid 43050137)
106. Fang Y, Li G, Ferrie AM. Non-invasive optical biosensor for assaying endogenous G protein-coupled receptors in adherent cells. J Pharmacol Toxicol Methods 2007;55:314-22 (Pubitemid 46436523)
107. Schroder R, Janssen N, Schmidt J, et al. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 2010;28:943-9
108. Peters MF, Scott CW. Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J Biomol Screen 2009;14:246-55
109. Dodgson K, Gedge L, Murray DC, et al. A 100K well screen for a muscarinic receptor using the Epic label-free system-a reflection on the benefits of the label-free approach to screening seven-transmembrane receptors. J Recept Signal Transduct Res 2009;29:163-72
110. McGuinness RP, Proctor JM, Gallant DL, et al. Enhanced selectivity screening of GPCR ligands using a label-free cell based assay technology. Comb Chem High Throughput Screen 2009;12:812-23
111. Gregory KJ, Hall NE, Tobin AB, et al. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 2010;285:7459-74
112. Kenakin T, Miller LJ. Seven Transmembrane receptors as shapeshifting proteins : the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010;62:265-304
113. Valant C, Aurelio L, Urmaliya VB, et al. Delineating the mode of action of adenosine A1 receptor allosteric modulators. Mol Pharmacol 2010;78:444-55
114. Koole C, Wootten D, Simms J, et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 2010;78:456-65
115. Evans BA, Broxton N, Merlin J, et al. Quantification of functional selectivity at the human {alpha}1A-Adrenoceptor. Mol Pharmacol 2011;79:298-307
116. Figueroa KW, Griffin MT, Ehlert FJ. Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. J Pharmacol Exp Ther 2009;328:331-42
117. Christopoulos A. Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol Sci 1998;19:351-7 (Pubitemid 29011723)
118. Black J, Leff P. Operational models of pharmacological agonism. Proceedings of the Royal Society of London. Series B, Containing papers of a Biological character. Royal Society (Great Britain) 1983;220(1219):141-62 (Pubitemid 14217337)